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Abstract The Infectious Diseases Working Party (AGIHO)
of the German Society of Hematology and Oncology
(DGHO) here presents its updated recommendations for the
treatment of documented fungal infections. Invasive fungal
infections are a main cause of morbidity and mortality in
cancer patients undergoing intensive chemotherapy regimens.
In recent years, new antifungal agents have been licensed, and
agents already approved have been studied in new indications.
The choice of the most appropriate antifungal treatment de-
pends on the fungal species suspected or identified, the pa-
tient’s risk factors (e.g., length and depth of neutropenia), and
the expected side effects. This guideline reviews the clinical
studies that served as a basis for the following recommenda-
tions. All recommendations including the levels of evidence
are summarized in tables to give the reader rapid access to the
information.
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Introduction
In cancer patients, invasive fungal disease (IFD) remains an
important complication causing considerable mortality and
morbidity. Chemotherapy or transplantation procedures are
often delayed or postponed in patients with IFD which might
lead to impaired overall survival. In recent years, new anti-
fungal agents have been licensed or agents already approved
have been studied in new indications, which is why the
Infectious Diseases Working Party (AGIHO) of the German
Society of Hematology and Oncology (DGHO) here presents
its updated recommendations.
The current version of the guideline focuses on patients
with solid tumors or hematologic malignancies and includes
treatment of acute invasive infections caused by the species
Aspergillus , Candida , Cryptococcus , Scedosporium , Fusar-
ium , Zygomycetes , and Trichosporon . Chronic or superficial
fungal infections were excluded. We hereby give an overview
of the treatment options for invasive fungal disease and clas-
sify the recommendations according to their evidence level.
Methods
Data Clinical studies and guidelines published in English
were searched via Medline from 1990 up to June 2012.
Studies published in form of abstracts were only considered
if their data lead to a change in the level of recommendation
for a given treatment.
Evidence criteria Wherever possible, evidence categories of
the “Infectious Diseases Society of America” (IDSA) were
integrated (Table 1) [80]. Evidence levels for treatment in
neutropenic patients were “downgraded” (e.g., from AII to
BII) if available studies only included a small proportion of
neutropenic patients or no neutropenic patients at all.
Assessment of license The status of license for the presented
medications was not considered, and substances are solely
recommended based on available clinical study data. There-
fore, the responsibility for a selected therapy is exclusively
that of the ordering physician. Currently used dosages of
available fungal agents are listed in Table 6.
Finding consensus These recommendations were first pre-
pared by a panel of experts in the field of infections in
immunocompromised patients during two meetings and then
circulated via e-mail. All recommendations and evidence
levels were then voted first via e-mail and then during a
meeting of the AGIHO consensus group general assembly.
Treatment of invasive Aspergillus infections
Acute invasive pulmonary aspergillosis (IPA) is the most
frequent manifestation of systemic aspergillosis in
Table 1 Categories indicating the strength of each recommendation for
or against its use, and grades indicating the quality of evidence on which
recommendations are based. Criteria of the IDSA [80]
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation for use
D Moderate evidence to support a recommendation against use
E Good evidence to support a recommendation against use
I Evidence from at least 1 properly randomized, controlled trial
II Evidence from at least 1 well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies
(preferably from more than one center); from multiple time series;
or from dramatic results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert committees
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neutropenic patients [162] with a fatality rate that ranges from
30 to 60 % [11, 116, 123]. Early treatment at first signs of
infection is mandatory and improves the chance of survival
(BIII) [25].
Neutropenic patients Although data are limited, the response to
liposomal amphotericin B is reduced by >20 % in the neutrope-
nic host (43 %) as compared to non-neutropenic patients (67 %)
with invasive aspergillosis as compared to voriconazole where
response rates were similar in patients with and without neutro-
penia (50.8 vs. 54.3 %, respectively) [35, 65].
Antifungal therapy
Azoles
Voriconazole In an open, non-comparative study, voriconazole
showed a response rate of 59 % in the primary treatment of
invasive aspergillosis and a 38 % response rate when used for
salvage treatment [41]. The randomized comparison between
voriconazole and amphotericin B deoxycholate (D-AmB)
(both followed by other licensed antifungal agents in the case
of failure/intolerance) included patients with a malignant un-
derlying disease or another immunocompromising condition.
In this study, voriconazole had a significantly higher response
and survival rate including less Aspergillus-related deaths and
side effects than D-AmB. Since then, voriconazole has been
established as the gold standard for treatment of invasive
aspergillosis [65, 186]. Although the study design has some
limitations (e.g., lack of details of administered antifungal
agents in the comparator arm and inclusion of cases without
sufficient evidence for IFD), we recommend voriconazole as
the standard therapy for aspergillosis (AI). In case of a different
first-line therapy, voriconazole is recommended for salvage
treatment of invasive aspergillosis (BII). In an observational
efficacy and safety analysis, clinical response with
voriconazole as monotherapy was observed in 42/72 patients
[76]. In addition, voriconazole is more active in vitro against
Aspergillus terreus compared to D-AmB [59, 91].
After oral or intravenous administration, adequate concen-
trations of voriconazole were documented in many body sites
including brain parenchyma [56]. However, a large variability
in trough plasma levels has been observed [130]. A recent
study demonstrated a positive correlation between plasma
levels, clinical efficacy, and toxicity. Plasma concentrations
of >1 mg/L were found to be correlated with response to
therapy. However, plasma levels >5.5 mg/L were associated
with neurotoxicity [131]. Therapeutic concentrations could
only be achieved with a dose of 2×200 mg oral voriconazole
in about 50 % of patients, increasing to about 70 % with 2×
300 mg and nearly 100 % with 2×400 mg given [131] (see
also “Therapeutic drug monitoring of antifungal agents”
section).
Main side effects of voriconazole therapy are reversible visual
disturbances in up to 40 % of patients. Primarily due to cyto-
chrome P450 metabolism, voriconazole can interact with a large
number of other drugs. Therefore, contraindications and co-
medications (e.g., vinca alkaloids, statins, chinidin) have to be
monitored closely.
Posaconazole Posaconazole was licensed for second-line ther-
apy of aspergillosis in 2005 by EMA. In a retrospective compar-
ison of posaconazole versus standard treatment (e.g., AmB lipid
formulations and itraconazole) in a historical control group,
patients (including neutropenic patients) demonstrated a re-
sponse rate of 42 versus 26 %, respectively [189]. The response
to posaconazole correlated with plasma concentrations [189].
Additionally, in a retrospective not stratified investigation, the
response rate of posaconazole compared favorably to high-dose
AmB lipid formulations (≥7.5 mg/kg) or caspofungin plus high-
dose lipid-AmB in salvage therapy for invasive aspergillosis.
Response rates were 40 versus 8 versus 11 %, respectively, in
143 patients with hematological malignancies [140]. Thus,
posaconazole is recommended as a salvage therapy in this patient
group (BII). Posaconazole is generally well tolerated, also in
long-term use [138]. The drug is a substrate of both uridine
diphosphate glucuronosyltransferase and the transporter P-
glycoprotein, but is not significantly metabolized by cytochrome
P450, although the compound inhibits isoenzyme 3A4 [50, 192].
Therefore, different potential interactions have to be considered if
co-medications are given. Posaconazole also demonstrates activ-
ity in mucormycosis, which is clinically difficult to distinguish
from aspergillosis of the lungs, paranasal sinuses, or CNS [181].
Up to now, posaconazole is only available as an oral suspension
and should be administered with food. The co-medication with a
proton pump inhibitor might limit the posaconazole exposure.
Echinocandins
Caspofungin A phase II study of caspofungin as first-line
therapy demonstrated survival rates of 66 % (6 weeks) and
53 % (12 weeks) in 61 patients with hematologic malignan-
cies [184]. Most patients were not in remission of their under-
lying disease, 72 % presented with severe neutropenia for
>10 days, and in contrast to other studies, aspergillosis had
to be proven or probable strictly according to European Or-
ganization for Research and Treatment of Cancer (EORTC)-
MSG criteria [10]. An EORTC study in allogeneic stem cell-
transplanted patients was stopped due to inadequate recruit-
ment with 42 patients enrolled. At week 6 and week 12, the
survival rate was 79 and 50 %, respectively [68]. In a pro-
spective observational registry, 12 out of 20 patients
responded to caspofungin first-line treatment [98]. In summa-
ry, the AGIHO working group considers caspofungin as a
therapeutic option in the first-line therapy (CII) (vote, 7:4, 3
abstentions).
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When used for salvage treatment, caspofungin resulted in a
response rate of 45–49 % in two non-comparative studies of
patients with invasive aspergillosis and failure of or intolerability
to standard antifungal therapy [100, 112]. A case collection of
118 patients demonstrated a response rate of 61 % [52]. In the
CAN-DO study, 45/81 patients responded to caspofungin treat-
ment [98]. As caspofungin is well tolerated, it is recommended
for salvage therapy (BII).
Micafungin Micafungin has been investigated mostly in sal-
vage therapy studies and retrospective analyses as mono- and
particularly combination therapy which resulted in efficacy
rates of about 25–36 % [40, 82]. Therefore, the role of
micafungin in the treatment of acute invasive aspergillosis
has not been clarified so far (CII).
Anidulafungin Data on anidulafungin as a monotherapy for
the treatment of invasive aspergillosis are too limited to allow
inclusion of this drug into therapy algorithms of invasive
aspergillosis (see “Combination therapy” section).
Amphotericin B formulations
Amphotericin B lipid complex (ABLC) A retrospective analysis
of a large company-based dataset (Collaborative Exchange of
Antifungal Research) showed a 44 % efficacy in about 400
patients with IA (55 % response in 42 neutropenic patients)
[31] and 31 % response rate in patients after allogeneic stem cell
transplantation [74], mainly in patients with second-line therapy
(BII). There are no sufficient data for first-line therapy (CIII).
Liposomal amphotericin B (L-AmB) Several non-comparative
studies with L-AmB for second-line therapy exist which in-
cluded only smaller numbers of patients and resulted in re-
sponse rates of 50–70 % [108, 147]. In a pooled efficacy
analysis, this resulted in a response rate of 47 % for the
treatment of invasive aspergillosis [32]. In a randomized stud-
y, L-AmBwas equally efficacious compared to D-AmB in the
first-line therapy of invasive mycosis [92], but the study was
not restricted to patients with IA. The efficacy of L-AmB
versus ABLC in the first-line therapy has been compared in
an analysis of eight open-label studies with more than 1,000
patients resulting in a response rate of 61 versus 46% favoring
L-AmB over ABLC [121]. A retrospective study in 158
consecutive patients with mainly acute leukemia or allogeneic
stem cell transplantation receiving L-AmB or ABLC for in-
vasive aspergillosis resulted in a poor outcome of both groups
(12 %) [58]. ABLC was associated with significantly higher
nephrotoxicity compared to L-AmB [58].
The studied dosages of L-AmB for treatment of invasive
aspergillosis are 1–10 mg/kg/day (manufacturer recommenda-
tion, 1–3mg/kg) [35, 43, 92]. A randomized study comparing L-
AmB 4 versus 1 mg/kg resulted in similar efficacy rates, but
survival at day 14 and response in patients with proven aspergil-
losis were higher in the 4-mg/kg arm [43]. A randomized com-
parison of L-AmB 3 versus 10 mg/kg (mainly cancer patients) in
first-line therapy of invasive aspergillosis showed equal efficacy
but an increased toxicity with the higher dosage [35]. The
response rate was high and comparable to voriconazole.
In summary, we recommend L-AmB (3 mg/kg) for the
first-line treatment with lesser strength than voriconazole
(AII), since all available trials did not compare L-AmB with
a standard treatment. L-AmB may be also used as second-line
treatment (BII) [180].
Amphotericin B deoxycholate (D-AmB) Until 2002, intrave-
nous therapy with D-AmB had been the therapeutic gold
standard for IA with response rates of 30–50 %. Maximum
tolerable daily dosages of up to 1.5 mg/kg have been recom-
mended. Comparative clinical studies on dose regimens are,
however, not available. Due to its high toxicity and inferiority
compared to voriconazole in a randomized controlled study
[65], we strongly recommend not to use D-AmB (EI).
Combination therapy
The benefit of combination of D-AmB plus 5-flucytosine
has not been substantiated by appropriate clinical trials.
There are limited data from uncontrolled trials with re-
sponse rates of 42 % for combinations of L-AmB and
caspofungin as primary or salvage therapy [81], 55 % for
combinations of caspofungin and polyenes or triazoles in
cancer patients [99], and a significantly reduced mortality
rate for patients receiving caspofungin plus voriconazole
versus voriconazole alone in refractory aspergillosis in a
historically controlled trial among stem cell transplant re-
cipients [102]. A randomized pilot study comparing the
combination of L-AmB plus caspofungin (standard dos-
ages) to high-dose L-AmB in patients with hematological
malignancies resulted in a better response with the combi-
nation at the end of treatment, but similar overall survival
after 12 weeks and the number of patients included (n =30)
was rather small [27]. A recent large prospective random-
ized trial comparing voriconazole monotherapy to
voriconazole plus anidulafungin for first-line therapy did
not show any superiority of the combination for the primary
endpoint of overall survival at week 6. In a post hoc anal-
ysis for patients with galactomannan-positive aspergillosis,
survival at week 6 was significantly better in the group with
the combination treatment. These data have not been pub-
lished in a peer-reviewed journal, and therefore, up to now
final assessment cannot be made (Marr abstract ECCMID
2012, LB 2812) (CIII). In summary, data of combination
treatment regimens are very limited, so that combinations
cannot generally be recommended and may be considered
for refractory disease and/or severely ill patients (CIII).
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Salvage therapy
It is important to differentiate between a replacement of first-
line therapy with another substance because of toxicity from
change of substance due to refractory infection. Generally,
given a stable clinical situation, a minimum of 14 days of
full-dose treatment is recommended before a reliable first
clinical response assessment can be done.
Apart from evident failure due to intrinsic resistance of the
pathogen (e.g., A . terreus to AmB), lack of adequate drug levels
(see “Therapeutic drug monitoring of antifungal agents”), intol-
erance, or severe organ toxicity, non-response of IA to an
established antifungal therapy should be stated with caution
[104, 163]. A temporary increase in the volume of pulmonary
lesions during the first week of treatment or neutrophil recovery
must not be misinterpreted as antifungal treatment failure [26].
Since most available studies for salvage therapy included pa-
tients who failed to respond to D-AmB as a first-line treatment,
no general conclusion can be drawn to salvage treatment after
failure of newer antifungal agents (e.g., triazoles and
echinocandins) (CIII).
Invasive aspergillosis occurring during posaconazole or
voriconazole prophylaxis Recommendations for the treat-
ment of invasive mycoses have to consider the prophylactic
regimens, but so far, studies in this field are lacking. There-
fore, the expert group recommends the switch to another class
of antifungal agent, but to take into account an inadequate
exposition to the prophylactic agent (CIII).
Duration of antifungal treatment
Generally, the antifungal therapy should be continued during
the period of neutropenia and until the manifestations of IA
have been completely resolved or are reduced to residual
scarring, up to 12 weeks [65] (BIII).
Other manifestations
Invasive sinus aspergillosis Severe Aspergillus sinusitis most
often occurs in allogeneic stem cell transplant recipients (2–
3 %) and is primarily caused by Aspergillus fumigatus or
Aspergillus flavus [42, 182]. Frequently, additional surgical
debridement is required (BII) (see “Interventional strategies”).
Overall, Aspergillus sinusitis has been associated with a mor-
tality rate of 26.1 % while treated with AmB formulations
[95]. Therapy recommendations do not differ from pulmonary
manifestations (see Table 2).
Aspergillosis of the CNS Aspergillus spp. rarely cause men-
ingitis or micro-abscesses of the brain, but macro-abscesses—
especially in severe immunosuppressed patients—are most
often caused by A . fumigatus or A . flavus . Patients with
aspergillosis within the CNS typically present with focal
neurological signs such as pareses or seizures. Comparable
studies regarding drug treatment of CNS aspergillosis do not
exist, but it is clear that the prior standard therapy with D-
AmB is not effective [161]. Due to its good permeability into
the cerebrospinal fluid, voriconazole is recommended for
primary treatment [152] and has shown a survival rate of
30–40 % [41, 159, 160] (AII). Successful therapy with L-
AmB has also been reported in case reports [77, 161] and
might be administered in case of contraindication, intolerance,
or poor response to voriconazole (BIII). A retrospective study
of 81 patients with CNS aspergillosis resulted in significantly
better survival in patients undergoing surgery [160]. There-
fore, surgical resection of singular lesions is recommended
together with systemic antifungal treatment (AII).
Treatment of invasive Candida infections
The most common causes of IFD in cancer patients are yeast
pathogens, in particular Candida albicans , followed by non-
Candida albicans species (e.g., Candida glabrata , Candida
krusei , Candida parapsilosis , Candida tropicalis) [122, 151,
183]. In patients with hematological malignancies primarily
Table 2 Treatment of
invasive Aspergillus in-
fections in hemato-onco-
logical patients
First-line treatment of invasive
pulmonary aspergillosis
Voriconazole AI
Liposomal AmB AII
Caspofungin CII
Micafungin CII
ABLC CIII
Anidulafungin + voriconazole CIII
D-AmB EI
Second-line treatment of invasive
pulmonary aspergillosis
Voriconazole BII
Caspofungin BII
Posaconazole BII
Liposomal AmB BII
ABLC BII
Micafungin CIII
Voriconazole + caspofungin CIII
CNS infection
Voriconazole AII
Liposomal AmB (≥5 mg/kg) BIII
Surgical intervention AII
Sinusitis
Antifungals: see invasive
pulmonary aspergillosis
Surgical intervention BII
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non-Candida albicans species (e.g., C . tropicalis , C . glabrata)
have been identified in most studies [83, 174, 183]. The proper
identification of the infecting Candida spp . is crucial for the
choice of antifungal therapy (e.g., fluconazole-resistantCandida
spp .) [178]. Due to frequent colonization with Candida species
in hospitalized patients, detection of yeasts in non-sterile mate-
rial is not sufficient to confirm invasive Candida infection.
Colonization index and Candida scores have been developed
to predict invasive Candida infections for non-neutropenic pa-
tients in the ICU [94], but are not validated for patients with
hematological malignancies. In patients with acute leukemia, the
degree of mucosal damage and profound neutropenia are the
most important risk factors for invasive Candida infection in
contrast to other patient groups at risk for IFD with other
“classical” risk factors (e.g., central venous catheters) [23,
141]. The high pathogen-related mortality, which may approach
50 %, should prompt immediate initiation of therapy in all
patients with suspected yeasts in the blood culture, as delays in
treatment result in an increased mortality [48, 111].
Neutropenic patients Although data are limited, the response
rate as shown for therapy with echinocandins or amphotericin B
formulations is reduced by approximately 15–20 % in neutrope-
nic host as compared to other (non-neutropenic) patients with
candidemia [86, 110, 128]. According to data from a large cohort
study in patients treated with ABLC, a favorable clinical re-
sponse was observed in 61 % of all patients infected with
Candida species, but was as low as 20 % in patients who were
neutropenic at the time of diagnosis or became neutropenic
during antifungal treatment [75].
Antifungal therapy
Azoles
A randomized clinical trial [5] and a cohort study [7] did not
show a significant difference in antifungal efficacy between
fluconazole (400 mg daily) and D-AmB (25–50 mg daily;
0.67 mg/kg daily) in neutropenic patients with systemic Can-
dida infection. There was a trend to a lower response to
antifungal treatment in patients with neutrophil counts
≥1,000/μl at enrolment treated with fluconazole (58 %) as
compared to D-AmB (74 %). However, in the small subset of
patients with neutrophil counts <1,000/μl, fluconazole
appeared to be superior to D-AmB (response rate 77 % for
fluconazole vs. 48 % for D-AmB).
Due to the better in vitro susceptibility of voriconazole in
non-Candida albicans species, this agent may provide an
alternative to fluconazole, but only data from salvage
therapy studies are available [135]. Neutropenic patients
were not included in a randomized trial comparing
voriconazole to the regimen of D-AmB followed by flu-
conazole in the primary treatment of candidemia [85].
Data on the effect of itraconazole and posaconazole in
candidemia are lacking.
Amphotericin B formulations
The major disadvantages of D-AmB are nephrotoxicity, hy-
pokalemia, and acute infusion-related side effects. Increasing
number of publications report long-term nephrotoxicity with
D-AmB resulting in inferior survival especially in stem cell
transplant patients [16, 61, 107, 180, 196].
A recent study comparing L-AmB with micafungin for
first-line treatment of invasive Candida infections demon-
strated a high efficacy of L-AmB [86]. Overall success at the
end of therapy was 89.6 % for micafungin and 89.5 % for L-
AmB, respectively. Efficacy was independent of the Candida
spp. and primary site of infection, as well as neutropenia
status, Acute Physiology and Chronic Health Evaluation
(APACHE) II score, and central venous catheter removal.
An analysis of eight open-label studies on D-AmB and
AmB lipid formulations showed an efficacy rate of 75 % in
ABLC-treated and 80 % in L-AmB treated patients with
invasive Candida infections [121]. Amphotericin B colloidal
dispersion (ABCD) is unavailable in Germany, and tolerabil-
ity is less favorable when compared to ABLC or L-AmB.
Echinocandins
The results of a study comparing fluconazole (800 mg on day
1 and then 400 mg daily) versus anidulafungin (200 mg on
day 1 and then 100 mg daily) demonstrated superiority of
anidulafungin (response rate 75 vs. 60 %) in the treatment of
candidemia and invasive Candida infections in a general
population with only few neutropenic patients (3 %) [143].
Anidulafungin fulfilled the criteria for non-inferiority in non-
neutropenic patients (AI). A subgroup analysis demonstrated
the superiority of anidulafungin compared to fluconazole in
patients diagnosed with C. albicans infections (95 vs. 81 %).
In general, echinocandins (anidulafungin, caspofungin, and
micafungin) have been tested for the treatment of candidemia in
various controlled clinical trials [86, 110, 143], but the number
of neutropenic patients in these trials was limited (max. 10 %).
A direct comparison of caspofungin and micafungin showed
similar efficacy and safety. In addition, no difference in safety or
efficacy was seen in patients treated with two different dosages
of micafungin (100 or 150 mg/day) [128]. Further studies com-
paring one echinocandin to another echinocandin are lacking.
Higher dosages of caspofungin (150 vs. 70/50 mg/day) and
micafungin (150 vs. 100 mg/day) showed a trend towards im-
proved efficacy in subgroups of patients (APACHE II score >20,
neutropenia) andmight be used in selected patients [19, 36, 128].
A reduced sensitivity to fluconazole (“susceptible dose de-
pendent”) is frequently seen in Candida species such as C.
glabrata and C. tropicalis . Non-Candida albicans infections
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are more common in patients with hematologic malignancies
than in those with solid tumors, which favors initial broad-
spectrum antifungal therapy with an echinocandin (e.g.,
anidulafungin, caspofungin, or micafungin) in this patient group
(BI) [66].
A switch to (oral) fluconazole (800 mg/day as loading
dose, followed by 400 mg/day) or voriconazole (6 mg/kg
bid as loading dose, followed by 4 mg/kg bid) is optional. If
a susceptible species has been confirmed, the patient is clini-
cally stable and has no prior azole exposure (BII) [127].
In summary, due to its good efficacy especially against
non-Candida albicans spp. as well as its good safety profile
and the importance of a fungicidal mode of action,
echinocandins or L-AmB may be regarded as the drug of
choice in severely ill, clinically instable patients with organ
dysfunction, especially in patients with neutropenia (BI). For
non-neutropenic patients, data on echinocandins, liposomal
AmB, and voriconazole allow a recommendation level of AI
(see Table 3). In non-neutropenic patients with no prior azole
exposure, fluconazole is an alternative for the treatment of
yeasts in the blood culture while awaiting susceptibility tests
(AI; vote, 8:4; abstentions, 2) (see Table 3).
Combination therapy
In non-neutropenic patients, the combination of fluconazole
(800 mg per day) plus placebo with fluconazole plus D-AmB
(0.7 mg/kg per day, with the placebo/D-AmB component
given only for the first 5–6 days) did not show antagonism, a
similar mortality but improved clinical outcome (69 % for Flu/
D-AmB vs. 56 % for Flu/Placebo) and more rapid eradication
of yeasts from bloodstream compared to fluconazole alone
[146]. However, in patients with cancer or hematological ma-
lignancies, there are no data about combination therapies for
invasive Candida infections.
Salvage therapy
Data on second-line therapy in cancer patients, in particular
during neutropenia, are limited to case reports and specific
recommendations cannot be given.
Duration of antifungal therapy
Duration of treatment in non-neutropenic patients is recommend-
ed for at least 14 days after the first negative blood culture and
resolution of signs and symptoms of candidemia (BIII) [127,
153, 178], but should be adapted in case of organ manifestations.
Acute disseminated candidosis
Acute disseminated candidosis is the most severe form of
systemic Candida infection in neutropenic patients. It is char-
acterized by hemodynamic instability, persistent positive
blood cultures, and deep organ and/or skin involvement. Pa-
tients present with sepsis, spiking fever, shaking chills, and
disseminated lesions of the skin and sometimes other organ
infections such as endophthalmitis or osteomyelitis [18, 109].
Echinocandins and L-AmB are recommended as initial anti-
fungal treatment (BIII).
In addition to fundoscopy, an abdominal ultrasound (liver,
spleen, kidneys) should be performed in neutropenic patients
with candidemia after bone marrow recovery to exclude
chronic disseminated infection/hepatosplenic candidosis that
may not be associated with clinical symptoms other than fever
(BIII).
Management of intravenous lines
Intravenous lines should be removed at initiation of anti-
fungal therapy whenever feasible (AII). If the central ve-
nous lines are retained, the duration of candidemia in-
creases (from 3 to 6 days) as does the mortality of patients
[22, 87, 145, 193]. The role of central venous catheter
removal in neutropenic patients is controversial as the gas-
trointestinal mucosa, damaged by cytotoxic chemotherapy,
is thought to be the main port of entry for yeasts [6, 142,
198]. However, as the central venous line might be colo-
nized, it is recommended that it should be removed also in
neutropenic patients (AII). If the catheter has to be kept in
place, patients should be treated with an echinocandin or L-
AmB (CII) as these agents have a better minimal inhibitory
concentration in biofilms [84].
Table 3 Treatment of invasive Candida infections in hemato-oncological
patients
Candidemia
Neutropenic patients
Echinocandins BI
Liposomal AmB BI
Non-neutropenic patients
Echinocandins AI
Liposomal AmB AI
Voriconazole AI
Fluconazole AI
Hepatosplenic candidosis
Neutropenic patients
Liposomal AmB/ABLC BIII
Echinocandins BIII
Voriconazole CIII
Non-neutropenic patients
Fluconazolea BIII
Steroids CIII
a If no prior azole exposure
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Chronic disseminated candidosis (CDC)
If fever persists after neutrophil recovery, hepatosplenic
candidosis should be considered in hematological patients.
CDC is usually not an acute life-threatening condition but may
require systemic antifungal therapy for months. After stabiliza-
tion of signs and symptoms, CDC is not a contraindication for
the continuation of chemotherapy or hematopoietic stem cell
transplantation [78, 125].
Data on antifungal treatment in patients with CDC are
limited to case series with D-AmB given as a single therapy
or in combination with flucytosine [172, 191], lipid formula-
tions of amphotericin B [190], fluconazole [3, 79], or
caspofungin [34]. Due to the need for prolonged antifungal
therapy, oral agents such as fluconazole (400–800mg/day) are
recommended if the Candida strain was isolated and proven
to be susceptible (BIII). Echinocandins or L-AmB should be
used as initial therapy in unstable or refractory patients (BIII).
Voriconazole is an alternative option (CIII). The duration of
antifungal therapy in patients with CDC should be individu-
alized and may be continued until the resolution of all radio-
graphic signs or calcification of the lesions. In contrast, newer
data suggest that hepatosplenic candidosis may represent an
immune reconstitution syndrome as steroids (in addition to
antifungal treatment) can lead to a rapid resolution of clinical
signs [93] (CIII). In stable patients, intravenous therapy may
be switched to oral medication (step down strategy). This
strategy has not been studied in CDC so far, but is regarded
as safe and effective in patients with candidemia (see above).
Other manifestations
CNS CNS infections caused by Candida spp. might be treat-
ed with L-Amb (BIII) or voriconazole (BIII) [70, 115, 157].
Animal studies show a better penetration of L-AmB into the
brain tissue as compared to ABLC [57]. Fluconazole might be
a treatment option for CNS Candida infection if the patient is
clinically stable, without prior azole exposure, not neutrope-
nic, and if sensitivity to this agent has been documented by
in vitro resistance testing (CIII). Preclinical data further sug-
gest that echinocandins (e.g., caspofungin) may be useful to
treat Candida infections of the CNS albeit the poor CNS
penetration of these agents have to be taken in account—at
least if the blood–brain barrier is intact [45].
Treatment should be continued for an additional 4 weeks
following the resolution of manifestations (BIII) [124, 127]. In
case of a brain abscess, additional drainage or surgical resec-
tion is recommended.
Urinary tract For urinary tract Candida infection, fluconazole
has been proven in mainly non-neutropenic patients and is the
drug of choice, if a susceptibleCandida spp. is cultured (AI). If a
urine catheter is in place, it should be removed (BII) [127, 153].
Treatment of mucormycosis
Mucormycosis is an emerging invasive fungal infection in
patients with hematological malignancies and allogeneic stem
cell transplantation. In neutropenic patients, it usually involves
the lung and causes high mortality rates. The clinical presenta-
tion is difficult to distinguish from invasive pulmonary asper-
gillosis [126, 148]. A reverse halo or atoll sign has been
described on computed tomography scans, but is not specific
for mucormycosis. Such ring-shaped consolidation surround-
ing a central infiltrate should prompt a diagnostic work-up
including bronchoalveolar lavage and biopsy [30, 49, 185].
Treatment combines surgical debridement and antifungal
treatment (AII). Surgery is often necessary to confirm diagnosis
and may be used to decrease the fungal burden [29, 54, 148,
167, 171].
For first-line antifungal treatment, options include a lipid-
based amphotericin B formulation or posaconazole. D-AmB
yielded inferior results and is nephrotoxic [29, 126, 148, 167,
180, [187]. ABLC treatment was published in small series only
[90, 148, 167, 188], while there are a larger number of reports
including one series of L-AmB treatment for mucormycosis [35,
126, 148, 154, 166, 167]. Posaconazole first-line treatment has
been reported in two small series [154, 167]. In a single series,
lipid-based amphotericin B has been combinedwith caspofungin
for rhino-orbital-cerebral diseases (CIII), a pattern not typical for
hematologic but rather for diabetic patients [144].
In second-line treatment, the same drugs were used either
for refractory disease or because of intolerance of the patient,
i.e., ABLC [90, 188], L-AmB [126], ABCD [67], or
posaconazole [54, 167, 181].
Voriconazole is inactive inmucormycosis, and breakthrough
infections during voriconazole exposure have been reported
from retrospective evaluations and various case reports [103].
However, prospective clinical trials on voriconazole prophy-
laxis did not confirm an increased incidence [101, 195].
Taken together, most data, including results of multivariate
prognostic factor analyses, support the use of L-AmB 5 mg/
kg/day (AII) and doses >5 up to 10 mg/kg/day (AIII), while
ABLC and posaconazole 4×200 mg/day are recommended
with lesser strength (BII) in the first-line treatment. Second-
line treatment with posaconazole is recommended (AII), while
all three lipid-based amphotericin B formulations are alterna-
tives (BII) (see Table 4). Use of D-AmB is strongly discour-
aged in any indication and at any dose (EI).
Treatment of cryptococcosis
The vast majority of clinical studies on treatment of cryptococ-
cosis have been performed in patients with AIDS, albeit pa-
tients with hemato-oncological malignancies might also be
affected [15, 24, 62]. Infections byCryptococcus spp.—mainly
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Cryptococcus neoformans orCryptococcus gattii—commonly
involve the CNS, but fungemia or disseminated infections
might also occur. Diagnosis is usually based on fungal cultures,
India ink smear examination, latex-antigen test, and PCR stud-
ies using cerebrospinal fluid. Treatment of CNS cryptococcosis
in hematological patients should comprise L-AmB together
with flucytosine (5-FC) (AIII), usually followed by mainte-
nance therapy with fluconazole [21, 24, 134] (see Table 5).
Second-line or salvage treatment options for CNS crypto-
coccosis include L-Amb as single agent (BI), ABLC (5 mg/kg)
(BIII), voriconazole (BIII), posaconazole (CIII), D-AmB com-
bined with voriconazole or fluconazole (BII), and voriconazole
combined with 5-FC (BII) [12, 60, 97, 120, 165]. Severe
cryptococcosis of the lungs or of other organ systems should
be treated like CNS cryptococcosis (CIII). Very few andmainly
preclinical data are available concerning treatment of crypto-
coccosis by other agents such as caspofungin or posaconazole.
Therefore, these agents should not be used in the clinical
routine setting to treat cryptococcosis (Table 6).
Treatment of fusariosis
Invasive fusariosis is a severe sporadic mold infection affect-
ing mainly neutropenic patients. It is associated with a very
high mortality rate of 50–80 % [28, 118, 119]. The skin and
the lungs are the most frequent sites of infection, albeit in-
volvement of the sinus, soft tissues, and fungemia or dissem-
inated infections occurs frequently [28]. Systematic prospec-
tive analyses on the treatment of Fusarium infections are still
lacking. Retrospective case series suggest that L-AmB might
be preferable in hematological patients who often receive
other nephrotoxic drugs (BII). Voriconazole has been used
within the last years with success to treat invasive fusariosis
(BII) ([96], Nucci et al. M-1234 ICAAC 2012). Posaconazole
(BIII) or ABLC (BIII) might be used as alternative treatment
options [28, 96, 118, 133, 135, 139] (see Table 5). Surgical
resection of necrotic tissues (e.g., skin), central venous line
removal, or in vitro resistance testing might be further
measures to improve the outcome of patients with invasive
fusariosis (CIII).
Treatment of Trichosporon infections
Trichosporon species underwent different taxonomies and are
genetically heterogeneous. Apart from colonization of skin or
mucosal membranes, these yeast-like pathogens may cause
deep-seated infections, mostly in immunocompromised pa-
tients, specifically those with hematologic malignancies.
Regarding treatment, there are no data from randomized
trials in cancer patients, and we recommend guiding therapy
by susceptibility tests. Conclusions are restricted by the fact
that the majority of studies are examining sensitivity with
Trichosporon asahii /beigelii ; other Trichosporon species
were less present and may differ in results.
Clinical data confirm that azoles improve response rates
(CIII) [4, 150, 169] and markedly voriconazole (B III) has
been used in patients with hematological malignancies [8, 9,
44, 46, 51, 150] (see Table 5). As highMIC values correspond
to low response rates in hematological patients receiving
amphotericin B [51] or an echinocandin [17, 53, 105], these
agents cannot be recommended as monotherapy (DIII). Clin-
ical data to recommend these agents in combination therapy
with each other or with an azole are too scarce to establish any
recommendation [14, 51, 71].
Treatment of Scedosporium infections
Pseudallescheria /Scedosporium species are opportunistic fun-
gal species causing life-threatening disseminated infections in
immunocompromised patients [55, 88, 149, 173]. The most
common pathogens are Scedosporium prolificans and
Scedosporium apiospermum (teleomorph Pseudallescheria
boydii ). Systemic infections with Scedosporium /Pseu-
dallescheria species are often refractory to treatment as these
pathogens are highly resistant to available antifungal agents
[37]. No treatment data from randomized trials exist for any
patient group, and available information about treatment out-
come only stems from case reports and case collections.
S. prolificans Grenouillet and coworkers describe 119 pa-
tients with systemic Scedosporium infections. Only 11/119
patients survived, resulting in a death rate of >90 % [55].
Reviewing the cases of the surviving patients, treatment of
systemic scedosporiosis should include a multimodal approach
using surgery, if possible, antifungal combination therapy, and
supportive measures of immune reconstitution (e.g., growth
factor support). Tintelnot and coworkers reported on nine
patients with an underlying hematologic malignancy, and all
nine died [173]. Taken together, voriconazole plus terbinafine
Table 4 Treatment of mucormycosis in hemato-oncological patients
First-line treatment
Liposomal AmB (≥5 mg/kg) AII
ABLC BII
Posaconazole BII
Lipid-based amphotericin B plus caspofungin CIII
Second-line treatment
Posaconazole AII
Liposomal AmB (≥5 mg/kg) BII
ABLC BII
Additional surgical debridement AII
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seems to give the most promising results (CIII) [20, 55, 72,
114, 173, 194]. Another alternative is L-AmB in a dosage of at
least 5 mg/kg (CIII) (see Table 5).
S. apiospermum Reports about S. apiospermum infections are
even scarcer. Besides single case reports [13, 38], 21 patients
with an underlying hematologic malignancy were reported
from MD Anderson Cancer Center, TX [89]. Mortality rate in
patients with disseminated S . apiospermum infection was
79%.Most survivors received a combination therapy consisting
of L-AmB and a triazole (voriconazole, posaconazole). Given
these data, the treatment recommendation for S . apiospermum
infection is L-AmB in a dosage of 5 mg/kg (BIII) or an azole
such as voriconazole or posaconazole (BIII) (see Table 5).
Therapeutic drug monitoring of antifungal agents
Bioavailability might have an impact on clinical efficacy, and
pharmacokinetic properties of antifungal agents vary substan-
tially. For flucytosine with its known association of plasma
concentration and toxicity, therapeutic drug monitoring has
broadly been established [47]. Meanwhile, several studies in-
vestigated triazole concentrations in plasma or serum and corre-
lations with clinical efficacy or toxicity. Most of these analyses
are limited to retrospective investigations and nearly all of them
focus on Aspergillus infections. In contrast to current triazoles,
plasma levels of echinocandins and systemic polyenes are com-
paratively stable, and sufficient concentrations are supported by
obligatory intravenous application. For these classes of
antifungal agents, monitoring of drug concentration is not re-
quired in general. For fluconazole, efficacy seems also to be
associated with dosage and achieved blood concentrations.
Voriconazole plasma concentrations show a broad range of
intra- and interindividual variation. This triazole is metabo-
lized at least by the isoenzymes 2C19, 2C9, and 3A4 of the
cytochrome P450 system, which can cause many potential
drug interactions [64, 168]. In addition, genetic variations of
isoenzyme 2C19 alter biodegradation of voriconazole signif-
icantly, and other factors including food and absorption may
change its bioavailability. Therefore, voriconazole plasma
concentrations cannot be predicted by dosage [132].
Small retrospective analyses showed an association be-
tween plasma concentrations and clinical response in the
treatment of invasive aspergillosis, but also an increased rate
of adverse events for high plasma concentrations (usually
above 5.0 or 5.5 mg/l) [41, 130, 175, 177]. A retrospective
analysis of nine clinical phase I to III trials revealed an
association between plasma concentration and clinical re-
sponse for all invasive fungal infection [176]. This could be
demonstrated separately for both Candida and Aspergillus
infections. On the basis of these studies, an improved rate of
global response can be expected in case of plasma concentra-
tions between 1 and 5.5 mg/l [176]. The retrospective design
and the incomplete documented timing for the drawing of
blood samples are major limitations of these investigations.
In a small prospective study comparing weight-adjusted
voriconazole therapy with drug monitoring-guided
voriconazole application for first-line or salvage therapy could
not demonstrate a significant difference in the primary end-
point of adverse events [129]. However, although only a rather
small number of patients were enrolled, the clinical response
was significantly better when voriconazole dosage was ad-
justed to the determined plasma concentrations. Voriconazole
concentrations were determined on day 3 after the start of
therapy and always 3 days after change of dosage. When
interpreting these results, it has to be kept in mind that the
study population consisted of Asians, and azole metabolism
enzyme patterns differ in Asians and Caucasians [129].
Posaconazole is currently available as oral solution only.
Absorption is limited and doses above 800 mg daily did not
increase plasma concentration [179]. Drug interaction, fasting
condition, and increased gastric pH, e.g., due to proton pump
inhibitor usage, may impair bioavailability [64, 156]. The
initial study of posaconazole for salvage therapy of IA already
included a post hoc analysis on the impact of plasma concen-
tration. Patients were divided in quartiles of rising drug con-
centration, which paralleled global response [189].
In summary, therapeutic drug monitoring for triazoles can be
used to improve clinical response (BII). Determination of
plasma/serum concentrations of voriconazole and posaconazole
should be considered at least in case of suspected breakthrough
infection, (suspected) lack of response despite sufficient
Table 5 Treatment of rare fungal infections in hemato-oncological
patients
Cryptococcus neoformans infections
Liposomal AmB (3–4 mg/kg) + 5-FC AIII
Fusariosis
Voriconazole BII
Liposomal AmB (≥5 mg/kg) BII
ABLC BIII
Scedosporium spp. infections
S . apiospermum (=Pseudallescheria boydii)
Liposomal AmB (≥5 mg/kg) BIII
Voriconazole BIII
Posaconazole BIII
S . prolificans
Voriconazole + terbinafin CIII
Liposomal AmB (≥5 mg/kg) CIII
Trichosporon spp. infections
Voriconazole BIII
Posaconazole CIII
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antifungal chemotherapy (adequate dosage, duration
≥2 weeks), suspected drug-related toxicity, switch from
intravenous to oral therapy, oral therapy, and limited re-
sorption because of nausea or diarrhea or specific co-
medications (e.g., proton pump inhibitor in case of
posaconazole). For voriconazole, a plasma concentration
between 1 and 5 mg/ml and for posaconazole above
0.7 mg/ml should be targeted for therapy of invasive
fungal infection (BII). Although optimal timing and quan-
tity of determined plasma concentrations have not been
sufficiently investigated, trough concentrations in steady
state might be appropriate (CIII). For flucytosine, a plasma
concentration of 30 to 80 mg/ml 2 h after application is
recommended (BII).
Empirical versus preemptive antifungal therapy
In recent years, there has been controversy about the optimal
therapeutic regimen for the initiation of antifungal therapy in
the setting of persistent fever in patients with prolonged
neutropenia.
Current guidelines recommend the implementation of anti-
fungal therapy in neutropenic patients as soon as there is no
defervescence after 3–5 days of treatment with broad-spectrum
antibiotic chemotherapy. This so-called empirical antifungal
strategy has drawbacks such as potential side effects and costs.
Preemptive treatment is commonly described as a diagnos-
tic-driven therapy (i.e., the diagnostic work-up shows suspi-
cious findings before initiation of antifungal treatment), where-
as empirical therapy is often referred to as fever-driven therapy.
Several recent studies compare the diagnostic-driven
approach with fever-driven antifungal therapy [2, 33, 63,
158, 170]: So far, the routine use of the diagnostic-driven
approach cannot be recommended as long as the current
diagnostic tools lack sensitivity and/or specificity and
treatment triggers are not clearly defined. Furthermore,
treatment delay might enhance mortality in this patient
population.
Some of these studies used microbiological tools for the
monitoring of fungal disease, e.g., fungal PCR techniques,
serum galactomannan, or β-D-glucan testing; some studies
asked for specific radiological signs such as a halo sign as
trigger for initiating preemptive antifungal therapy. The poly-
merase chain reaction based-preemptive antifungal therapy
creates a major difficulty, as this method is not yet established
as a standard diagnostic for fungal infections. The assessment
of outcomes was different and shows the difficulty in dealing
with therapeutic strategies: some studies used survival of the
invasive fungal infection as the information of choice, where-
as others investigated the consumption and costs of antifungal
treatment.
In order to use a diagnostic-driven therapeutic approach, a
stringent assessment of clinical signs and symptoms and mi-
crobiological and radiological diagnostics must be warranted
(BIII), e.g., monitoring of galactomannan at least twice week-
ly, performance of high-resolution computed tomography of
the chest and the paranasal sinuses in persistent fever despite
adequate antibacterial antibiotic chemotherapy, and regular
clinical examination of the patient.
Interventional strategies
Surgical intervention
Potential indications for a surgical intervention in pulmonary
fungal infection might be (1) acute hemoptysis, (2) need of
Table 6 Daily doses of antifungal agents for the treatment of IFD
Daily dose Loading dose day 1 Dose adjustments
Caspofungin weight ≤80 kg; 50 mg
weight >80 kg: 70 mg
70 mg Liver cirrhosis: Child–Pugh score B: 35 mg/day; C: no data
Micafungin 100 mg
Anidulafungin 100 mg 200 mg
Liposomal AmB 3 mg/kg CNS 3–5 mg/kg; mucormycosis ≥5 mg/kg
ABLC 5 mg/kg
Voriconazole i.v. 2×4 mg/kg 2×6 mg/kg Creatinine clearance <50 ml/min: preferably
oral administration; liver cirrhosis: see below
Voriconazole p.o. 2×200 mg 2×400 mg Consider 2×300 mg to obtain plasma levels comparable
with 4 mg/kg i.v.; liver cirrhosis: Child–Pugh score A–B:
50 % dose reduction; C: no data
Posaconazole 2×400 mg 4×200 mg in case of insufficient enteral nutrition
Fluconazole i.v./p.o. 400–800 mg 800 mg Creatinine clearance 11–50 ml/min: 50 % dose reduction
5-Flucytosine 150 mg/kg divided into 4 doses
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histological diagnostics, (3) removal of residual infiltrates
prior to the next chemotherapy cycle, (4) prevention of bleed-
ing in the case of fungal lesions with vessel involvement, and
(5) reduction of fungal burden (e.g., in mucormycosis).
Hemoptysis occurs in pulmonary aspergillosis or
mucormycosis in up to 30 % of the cases, frequently during
the phase of neutrophil recovery. The resection of residual
infiltrations, combined with antifungal therapy, may result in a
local control of the fungal infection in patients requiring further
intensive chemotherapy or transplantation [117]. A monocenter
study found a reduction in mortality from 41 to 14 % after
introduction of systemic computed tomography (CT) examina-
tions followed by frequent use of surgical resections when
compared to a historical control [25]. In another study compris-
ing 41 patients with hematologic diseases undergoing surgical
intervention of their IPA, the mortality within 30 days was about
10 %, fungal relapse occurred in 10 %, and the overall survival
at 6months was 65% [106]. Danner et al. reviewed 198 patients
having undergone surgery for IPA. They found a day-30 mor-
tality of 12 % and a 6-month survival of 50 % [39].
However, experience in surgical treatment of IPA is based on
data from the era of D-AmB. With the newer antifungal agents,
surgical intervention seems to have less importance. Therefore,
we recommend surgical resections for the above-listed circum-
stances in accordance to other guidelines [186] (BII).
In sinu-nasal aspergillosis, additional surgical intervention
may be necessary in individual cases (BII) [186]. In aspergil-
losis of the CNS, surgical resection should be considered (AII)
as it seems to improve outcome [160].
Drug instillation
For treatment of refractory abscesses or caverns (e.g., in the
lung or brain) in which surgical intervention is not feasible, a
drainage as well as a local drug instillation may be considered.
Here, antifungal preparations (commonly containing AmB) or
disinfecting substances such as sodium iodide or potassium
iodide can be administered (CIII) [197].
Embolization
Embolization may be considered in the case of large pulmo-
nary infiltrates where the occurrence of hemoptysis due to
vessel erosion is likely, including the development of aneu-
rysms. The vessel involvement of fungal lesions should be
diagnosed by a spiral CT. If confirmed, the bronchial and
pulmonary vessels can be embolized (CIII) [69].
Immunotherapy and granulocyte transfusion
Colony-stimulating factors The application of hematopoietic
growth factor should be considered on an individual case-by-
case basis, according to the recommendations of the EORTC
(B III) [1].
Tcell therapy A study from the Perugia group showed a more
rapid reduction in the galactomannan antigen titer and a better
outcome in patients with IPA after haplo-identical stem cell
transplantation, when receiving T cells raised against fungal
pathogens [136]. Further studies with the transfer of immune
effector cells and better tools to determine the numbers of
fungus-specific T cells prior and after cellular immunotherapy
are urgently required. So far, this kind of therapeutic option is
still considered experimental.
Granulocyte transfusions Compared to the 1980s, granulo-
cyte harvest and granulocyte function have clearly improved
by stimulating donors with G-CSF [137]. Presently, interven-
tional granulocyte transfusions are being studied in clinical
trials. In a retrospective case-controlled study on 74 stem cell
transplant patients, there was a tendency toward worse out-
come in the transfused patients [73]. Another case-controlled
study in patients with candidemia showed an equal short-term
survival rate, but the group with granulocyte transfusions had
higher risk factors whichmay be interpreted as a benefit of this
option [155]. In 31 patients with invasive fungal infection (17
possible infections) undergoing granulocyte transfusions,
78 % survived [113].
A randomized study with prophylactic granulocyte
transfusion thrice a week in patients with neutropenic fever
and pulmonary infiltrates or a history of proven IFD failed
to confirm the benefit of this procedure [164]. Currently,
clear benefit of granulocyte transfusions in invasive myco-
ses has not been doubtlessly clarified [137]. However, it
might be considered as a treatment option in selected patients
(CIII).
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